RxDoctor Payments Data

Jeffrey Brannen, DO

Gastroenterology · Clive, IANPI 1972616316

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 58.9% of the total.

$1,248in general payments, 2019–2025

Across 98 payments — averaging $12.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Ardelyx, Inc.$92
  • Takeda Pharmaceuticals U.S.A., Inc.$92
  • Gilead$90
  • Regeneron Healthcare Solutions, Inc.$54
  • Aimmune Therapeutics, Inc.$47
  • plus $138 from 7 others

What the payments were for

  • Food & beverage$1,248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,248 in reported general payments places this provider in the 65th percentile of 113 gastroenterology providers in Iowa.

See all gastroenterology providers in Iowa

Medicare billing

Part B allowed, 2024
$80,244
Medicare patients
417
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin51$156,049
LinzessLinaclotide185$114,482
Humira PenAdalimumab14$95,654
IbsrelaTenapanor Hcl43$74,165
CreonLipase/Protease/Amylase44$71,130
ZenpepLipase/Protease/Amylase18$48,943
Dexlansoprazole DrDexlansoprazole266$48,745
Mesalamine96$26,517
Budesonide DrBudesonide74$16,968
SutabSod Sulf/Pot Chloride/Mag Sulf88$14,194
Mesalamine DrMesalamine26$10,326
Colestipol Hcl107$8,703
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C54$7,816
TrulancePlecanatide14$7,749
Mesalamine ErMesalamine34$7,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$736$185,612229 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu, Trulance$31$171,614119 claims
Ardelyx, Inc.Ibsrela$92$74,16543 claims
Aimmune Therapeutics, Inc.Zenpep$47$48,94318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 113 gastroenterology providers in Iowa.

Other gastroenterology in Clive

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →